228. 閉塞性細気管支炎 [臨床試験数:92,薬物数:125(DrugBank:34),標的遺伝子数:33,標的パスウェイ数:152

Searched query = "Bronchiolitis obliterans", "Obliterating bronchiolitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-002022-12-SE06/08/201515/10/2014European Trial of Pirfenidone in BOS (EPOS).A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s).
MedDRA version: 20.0Level: LLTClassification code 10049202Term: Bronchiolitis obliteransSystem Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Esbriet
Product Name: Pirfenidone
INN or Proposed INN: PIRFENIDONE
Other descriptive name: 5-Methyl-1-Phenyl-2-1-(H)-Pyridone
Clinical Trials Unit, RigshospitaletNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
80Phase 2Belgium;Denmark;Netherlands;Germany;United Kingdom;Sweden
2EUCTR2014-002022-12-BE10/03/201515/10/2014European Trial of Pirfenidone in BOS (EPOS).A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s).
MedDRA version: 20.0Level: LLTClassification code 10049202Term: Bronchiolitis obliteransSystem Organ Class: 100000015490;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Esbriet
Product Name: Pirfenidone
INN or Proposed INN: PIRFENIDONE
Other descriptive name: 5-Methyl-1-Phenyl-2-1-(H)-Pyridone
Clinical Trials Unit, RigshospitaletNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
80Phase 2Belgium;Denmark;Netherlands;Germany;United Kingdom;Sweden
3EUCTR2014-002022-12-DK15/12/201404/11/2014European Trial of Pirfenidone in BOS (EPOS).A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s).
MedDRA version: 20.0Level: LLTClassification code 10049202Term: Bronchiolitis obliteransSystem Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Esbriet
Product Name: Pirfenidone
INN or Proposed INN: PIRFENIDONE
Other descriptive name: 5-Methyl-1-Phenyl-2-1-(H)-Pyridone
Clinical Trials Unit, RigshospitaletNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
90Phase 2Belgium;Denmark;Netherlands;Germany;United Kingdom;Sweden